Advanced Search

 

Study ID Status Title Patient Level Data
AZ3106242 Completed A Double-Blind, Randomised, Placebo-Controlled, Parallel Group Study to Investigate the Effects of SB-742457, Donepezil and Placebo on Cognition in Subjects with Mild to Moderate Alzheimer’s Disease
AZ3110865 Completed Study AZ3110865, a study comparing SB-742457 or donepezil versus placebo in subjects with mild-to-moderate Alzheimer’s disease
AZ3110866 Completed Study AZ3110866, a fixed dose study of SB-742457 versus placebo when added to existing donepezil treatment in subjects with mild-to-moderate Alzheimer’s disease
AZA30002 Completed An open, non-controlled study to investigate the safety and efficacy of 12 to 96 weeks of treatment with telmisartan when administered to patients with hypertension.
AZA30003 Completed A prospective double-blind, randomised, placebo-controlled, 3 week crossover study to investigate the effects of telmisartan 40mg on arterial compliance and endothelial function in type 2 diabetes subjects with essential hypertension.
AZA30004 Completed A prospective, double-blind, randomised, placebo-controlled, 3 week cross-over study to investigate the effects of telmisartan on pulse wave velocity and arterial compliance in subjects with isolated systolic hypertension.
AZA30005 Completed A prospective, randomised, open-label, blinded endpoint (PROBE), parallel group study comparing a one-step response based titration regimen of 12 weeks duration of telmisartan with enalapril in patients with essential hypertension.
AZA30006 Completed A prospective, randomized, double-blind, parallel group study to compare the adjunctive effect of telmisartan with existing antihypertensive therapy in patients with essential hypertension that is uncontrolled on current therapy.
AZA30012 Completed An open label randomized study of efficacy and safety of telmisartan administered during 12 weeks in combination and as sequential single therapy (TEAM study).
AZA30013 Completed Comparison, with self measurements of blood pressure, of residual efficacy of telmisartan and perindopril in mild to moderate essential hypertension (EVERESTE study).
AZA30015 Completed P.R.O.B.E. (Prospective, Randomized, Open-label, Blinded Endpoint) multicentre, parallel-group study to evaluate the efficacy of telmisartan 40/80 mg vs losartan 50/100 mg in patients with mild/moderate hypertension
AZA30016 Completed P.R.O.B.E. (Prospective, Randomized, Open label, Blinded Endpoint) multicentre, parallel group study to evaluate the efficacy of telmisartan 40/80 mg vs lisinopril 10/20 mg in the reduction of progressive renal impairment in hypertensive subjects with type 2 diabetes.
AZA30020 Completed Acute effects of the Angiotensin 1 receptor blockade, telmisartan 80 mg, on the nitric oxide flow-mediated vasodilation of radial artery, in healthy volunteers
AZA40052; AZA40053 Completed Telmisartan Therapy for Hypertension in a Primary-Care Setting: A Canadian Observational Study
AZL10001 Completed An Evaluation of the Bioequivalence of a Combined Formulated Tablet (300/150/300mg abacavir/lamivudine/zidovudine) Compared to ZIAGEN (abacavir) 300mg tablet, EPIVIR (lamivudine) 150mg tablet, and RETROVIR (zidovudine) 300mg tablet Administered Concurrently and the Effect of Food on Absorption i ...
AZL10002 Completed An Evaluation of the Steady-State Pharmacokinetics of abacavir, lamivudine, and zidovudine following administration of a Combined Formulated Tablet (300/150/300mg abacavir/lamivudine/zidovudine) versus ZIAGEN (300mg abacavir) and COMBIVIR (150/300mg lamivudine/zidovudine) in Subjects with HIV-1 ...
AZL30002 Completed A Phase IIIb, Randomised, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of a Triple Combination Tablet (Trizivir) [abacavir, lamivudine, zidovudine] Versus Continued Antiretroviral Triple Therapy in HIV-1 Infected Subjects with Undetectable Plasma HIV-1 RNA Levels (TRIZAL)
AZL30004 Completed A Phase IIIb/IV, Randomised, Open-Label, Multicentre Study to Evaluate the Efficacy, Safety and Tolerability of TRIZIVIR plus Efavirenz (Quad) Over 72 Weeks Versus Quad Therapy for 48 Weeks Followed by TRIZIVIR Alone for 24 Weeks Versus Quad Therapy for a minimum of 24 Weeks Followed by TRIZIVIR ...
AZL30004_1 Completed A Phase IIIb/IV, Randomised, Open-Label, Multicentre Study to Evaluate the Efficacy, Safety and Tolerability ofTRIZIVIR. plus Efavirenz (Quad) Over 72 Weeks Versus Quad Therapy for 48 Weeks Followed by TRIZIVIR Alone for24 Weeks Versus Quad Therapy for a minimum of 24 Weeks Followed by TRIZIVIR ...
AZL30006 Completed A Phase IIIb/IV, Randomized, Open Label, Multicenter, Pilot Trial to Explore the Safety and Tolerability of GW433908 +/- Ritonavir (1400mg twice daily or 700mg/100mg twice daily) When Used in Combination with a Zidovudine-containing Regimen (TRIZIVIR or COMBIVIR twice daily) Over a 24 Week Period in Antiretroviral Therapy Naive HIV-1 Infected Subjects.
AZL40001 Completed An open-label, single arm, multicentre, pilot phase IV study to evaluate the efficacy and safety of a potent combination therapy (Trizivir + Efavirenz) in antiretroviral nave adults with a CD4+ cell count <200mm3 over a 48-week treatment period (TETRA Trizivir Efavirenz TReAtment)
AZLF3002 Completed Multicentre, open-label, pilot study to evaluate the efficacy and safety of a triple therapy combining AZT/3TC/ABC as a combined tablet of Trizivir, in HIV-infected patients with an undetectable viral load after quadruple therapy (COM, ABC, EFV) during CNAF 3008 study (La Francilienne).
AZLF3004 Completed An Open-label study to evaluate long-term (48 weeks) safety and efficacy of switch to TRIZIVIR after first line quadruple induction therapy: AZLF3004-Trisud
B04-689PK-P05P2 Completed A two-way, steady-state, fasting, dosage form proportionality study of 150 mg Wellbutrin XL™ tablets and 450 mg bupropion extended-release tablets in normal healthy non-smoking male and female subjects.
B04-696PK-P05P2 Completed A two-way, steady-state, fasting, dosage form proportionality study of 150 mg Wellbutrin XL™ tablets and 450 mg bupropion extended-release tablets in normal healthy non-smoking male and female subjects.

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.